Table 2 Treatment effects for all contrast in terms of pain (pain VAS) along with 95% credible interval and probability that treatment is better than the comparator
Intervention | Comparator | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Placebo | MTX | aTNF | Tocilizumab | aTNF + MTX | Abatacept + MTX | Anakinra + MTX | Tocilizumab + MTX | ||
Placebo | Estimate | 0 | 14.71 | 20.17 | 31.28 | 32.53 | 37.63 | 22.00 | 30.71 |
95% CrI | (-3.85, 33.43) | (12.33, 29.73) | (18.69, 45.21) | (13.46, 52.09) | (6.71, 67.22) | (0.86, 42.52) | (15.14, 46.97) | ||
P(better) | 5% | <1% | <1% | <1% | 1% | 2% | <1% | ||
MTX | Estimate | -14.71 | 0 | 5.42 | 16.55 | 17.85 | 22.98 | 7.29 | 15.97 |
95% CrI | (-33.43, 3.85) | (-10.37, 24.07) | (3.81, 31.31) | (13.02, 23.08) | (-1.54, 47.31) | (-2.54, 16.69) | (6.26, 26.34) | ||
P(better) | 95% | 22% | 1% | <1% | 3% | 5% | <1% | ||
aTNF | Estimate | -20.17 | -5.42 | 0 | 11.09 | 12.40 | 17.27 | 1.84 | 10.60 |
95% CrI | (-29.73, -12.33) | (-24.07, 10.37) | (0.09, 21.3) | (-6.63, 29.01) | (-13.17, 45.84) | (-19.57, 19.71) | (-4.53, 23.59) | ||
P(better) | >99% | 78% | 2% | 7% | 12% | 40% | 6% | ||
Tocilizumab | Estimate | -31.28 | -16.55 | -11.09 | 0 | 1.30 | 6.23 | -9.29 | -0.56 |
95% CrI | (-45.21, -18.69) | (-31.31, -3.81) | (-21.3, -0.09) | (-13.98, 15.15) | (-21.98, 33.48) | (-27.22, 6.19) | (-10.64, 8.41) | ||
P(better) | >99% | 99% | 98% | 41% | 33% | 91% | 56% | ||
aTNF + MTX | Estimate | -32.53 | -17.85 | -12.40 | -1.30 | 0 | 5.06 | -10.60 | -1.85 |
95% CrI | (-52.09, -13.46) | (-23.08, -13.02) | (-29.01, 6.63) | (-15.15, 13.98) | (-19.92, 29.83) | (-21.84, -0.05) | (-12.93, 9.48) | ||
P(better) | >99% | >99% | 93% | 59% | 35% | 98% | 65% | ||
Abatacept + MTX | Estimate | -37.63 | -22.98 | -17.27 | -6.23 | -5.06 | 0 | -15.61 | -6.93 |
95% CrI | (-67.22, -6.71) | (-47.31, 1.54) | (-45.84, 13.17) | (-33.48, 21.98) | (-29.83, 19.92) | (-42.08, 10.48) | (-33.04, 19.51) | ||
P(better) | 99% | 97% | 88% | 67% | 65% | 89% | 70% | ||
Anakinra + MTX | Estimate | -22.00 | -7.29 | -1.84 | 9.29 | 10.60 | 15.61 | 0 | 8.73 |
95% CrI | (-42.52, -0.86) | (-16.69, 2.54) | (-19.71, 19.57) | (-6.19, 27.22) | (0.05, 21.84) | (-10.48, 42.08) | (-4.56, 23.05) | ||
P(better) | 98% | 95% | 60% | 9% | 2% | 11% | 7% | ||
Tocilizumab + MTX | Estimate | -30.71 | -15.97 | -10.60 | 0.56 | 1.85 | 6.93 | -8.73 | 0 |
95% CrI | (-46.97, -15.14) | (-26.34, -6.26) | (-23.59, 4.53) | (-8.41, 10.64) | (-9.48, 12.93) | (-19.51, 33.04) | (-23.05, 4.56) | ||
P(better) | >99% | >99% | 94% | 44% | 35% | 30% | 93% | ||